Vaginal toxicity after high-dose-rate endovaginal brachytherapy: 20 years of results.

To evaluate vaginal toxicity (primary endpoint) and local control (secondary endpoint) in patients with endometrial cancer who underwent primary surgery and adjuvant high-dose-rate (HDR) endovaginal brachytherapy (BT).